Page last updated: 2024-10-22

amifostine anhydrous and Fibrosis, Radiation

amifostine anhydrous has been researched along with Fibrosis, Radiation in 14 studies

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.

Research Excerpts

ExcerptRelevanceReference
" We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy."3.71Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002)
"radiotherapy plus amifostine for cancer treatment."2.43Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. ( Clark, LG; Clark, OA; Sasse, AD; Sasse, EC, 2006)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's13 (92.86)29.6817
2010's1 (7.14)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Koukourakis, MI2
Panteliadou, M1
Abatzoglou, IM1
Sismanidou, K1
Sivridis, E2
Giatromanolaki, A2
Antonadou, D4
Throuvalas, N3
Petridis, A2
Bolanos, N2
Sagriotis, A2
Synodinou, M3
Choi, NC1
Veslemes, M1
Komaki, R3
Lee, JS2
Milas, L3
Lee, HK1
Fossella, FV3
Herbst, RS1
Allen, PK2
Liao, Z3
Stevens, CW2
Lu, C1
Zinner, RG1
Papadimitrakopoulou, VA1
Kies, MS1
Blumenschein, GR1
Pisters, KM1
Glisson, BS1
Kurie, J2
Kaplan, B2
Garza, VP1
Mooring, D1
Tucker, SL1
Cox, JD2
Mehta, V2
Gopal, R1
Chang, JY1
Wu, X1
Travis, E1
Spitz, MR1
Wynn, RB1
Sasse, AD1
Clark, LG1
Sasse, EC1
Clark, OA1
Coliarakis, N1
Athanassiou, H1
Kouveli, A1
Verigos, C1
Georgakopoulos, G1
Panoussaki, K1
Karageorgis, P1
Kouroussis, C1
Kakolyris, S1
Frangiadaki, C1
Retalis, G1
Georgoulias, V1
Allen, P1
Kelly, JF1
Zinner, R1
Papadimitrakopoulou, V1
Khuri, F1
Glisson, B1
Pisters, K1
Herbst, R1
Ro, J1
Thames, HD1
Hong, WK1

Reviews

4 reviews available for amifostine anhydrous and Fibrosis, Radiation

ArticleYear
Radioprotective effect of amifostine in radiation pneumonitis.
    Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18

    Topics: Amifostine; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic

2003
Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18

    Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung;

2004
Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies.
    Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 3

    Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combine

2005
Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis.
    International journal of radiation oncology, biology, physics, 2006, Mar-01, Volume: 64, Issue:3

    Topics: Amifostine; Cystitis; Deglutition Disorders; Esophagitis; Humans; Neoplasms; Radiation Injuries; Rad

2006

Trials

8 trials available for amifostine anhydrous and Fibrosis, Radiation

ArticleYear
Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
    International journal of radiation oncology, biology, physics, 2003, Oct-01, Volume: 57, Issue:2

    Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell L

2003
Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:6 Suppl 18

    Topics: Aged; Amifostine; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modal

2003
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
    International journal of radiation oncology, biology, physics, 2004, Apr-01, Volume: 58, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Amifostine; Antineoplastic Combined Chemotherapy Pr

2004
Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
    Seminars in oncology, 2004, Volume: 31, Issue:6 Suppl 18

    Topics: Amifostine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung;

2004
Mutagen sensitivity may predict lung protection by amifostine for patients with locally advanced non-small cell lung cancer treated by chemoradiotherapy.
    Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 3

    Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Non-S

2005
Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Acute Disease; Amifostine; Esophagitis; Female; Humans; Lung Neoplasms; Male; Middle Aged; Premedica

2001
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
    Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1

    Topics: Adult; Aged; Amifostine; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Combined

2002
Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
    Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1

    Topics: Acute Disease; Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality

2002

Other Studies

3 other studies available for amifostine anhydrous and Fibrosis, Radiation

ArticleYear
Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
    International journal of radiation oncology, biology, physics, 2013, Jan-01, Volume: 85, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Amifostine; Breast Neoplasms; Case-Control Studies; Combined Modalit

2013
Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical
    Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 3

    Topics: Amifostine; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topi

2005
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas

2002